In the study performed by Michot et al. in France in 2020 (28) and Aziz et al. in 2021 in the United States (USA) (29), tocilizumab was introduced as a monoclonal antibody blocking the interleukin-6 receptor which was applied as an important and effective immunosuppressant in the patients suffering from COVID-19 (28, 29). This evidence concerns the gene IL6R and COVID-19.